- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05327114
Studie účinnosti a bezpečnosti nipokalimabu pro dospělé s chronickou zánětlivou demyelinizační polyneuropatií (CIDP)
Fáze 2/3, vícestupňová, multicentrická, randomizovaná, dvojitě zaslepená, placebem kontrolovaná paralelní skupinová odvykací studie k vyhodnocení účinnosti a bezpečnosti nipokalimabu podávaného dospělým s chronickou zánětlivou demyelinizační polyneuropatií (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 3
Rozšířený přístup
Kontakty a umístění
Studijní kontakt
- Jméno: Study Contact
- Telefonní číslo: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studijní místa
-
-
-
Buenos Aires, Argentina, C1199ABB
- Aktivní, ne nábor
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1428AQK
- Nábor
- Instituto Fleni
-
Buenos Aires, Argentina, C1428
- Dokončeno
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentina, 2900
- Nábor
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Austrálie, 3004
- Dokončeno
- The Alfred Hospital
-
Parkwood, Austrálie, 4215
- Dokončeno
- Gold Coast University Hospital
-
-
-
-
-
Bordeaux, Francie, 33000
- Dokončeno
- CHU Bordeaux
-
Bron, Francie, 69699
- Dokončeno
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, Francie, 94270
- Aktivní, ne nábor
- Hopital de Bicetre
-
Marseille, Francie, 13385
- Aktivní, ne nábor
- Hopital de la Timone
-
Nice, Francie, 06000
- Aktivní, ne nábor
- Hopital PASTEUR
-
Nîmes, Francie, 30029
- Aktivní, ne nábor
- CHU Nimes Hopital Caremeau
-
Paris, Francie, 75013
- Dokončeno
- Hopital de la Pitie Salpetriere
-
Paris, Francie, 75019
- Dokončeno
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, Francie, 67200
- Aktivní, ne nábor
- CHRU Strasbourg
-
-
-
-
-
Catania, Itálie, 95123
- Dokončeno
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Itálie, 16132
- Dokončeno
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Itálie, 20144
- Dokončeno
- Casa di Cura del Policlinico
-
Milan, Itálie, 20133
- Dokončeno
- Istituto Neurologico Carlo Besta
-
Naples, Itálie, 80131
- Aktivní, ne nábor
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Itálie, 10043
- Dokončeno
- Aou San Luigi Gonzaga
-
Pavia, Itálie, 27100
- Dokončeno
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Itálie, 00168
- Dokončeno
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Itálie, 20086
- Dokončeno
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Asahikawa, Japonsko, 070-0901
- Aktivní, ne nábor
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Japonsko, 113 8519
- Aktivní, ne nábor
- Institute of Science Tokyo Hospital
-
Chiba, Japonsko, 260-8677
- Dokončeno
- Chiba University Hospital
-
Hamamatsu, Japonsko, 430-8558
- Aktivní, ne nábor
- Seirei Hamamatsu General Hospital
-
Isehara, Japonsko, 259-1193
- Aktivní, ne nábor
- Tokai University Hospital
-
Kobe, Japonsko, 650 0047
- Dokončeno
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Japonsko, 187-8551
- Aktivní, ne nábor
- National Center of Neurology and Psychiatry
-
Koshigaya, Japonsko, 343-8555
- Aktivní, ne nábor
- Saitama Medical Center
-
Kumamoto, Japonsko, 860-8556
- Dokončeno
- Kumamoto University Hospital
-
Nagoya, Japonsko, 466-8560
- Aktivní, ne nábor
- Nagoya University Hospital
-
Nagoya, Japonsko, 455-8530
- Aktivní, ne nábor
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Japonsko, 589 8511
- Dokončeno
- Kindai University Hospital
-
Sendai, Japonsko, 983-8520
- Aktivní, ne nábor
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Japonsko, 321 0293
- Dokončeno
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Japonsko, 162-8666
- Dokončeno
- Tokyo Women's Medical University Hospital
-
Tenri, Japonsko, 632-0015
- Dokončeno
- Tenri Hospital
-
Toon-shi, Japonsko, 791-0295
- Dokončeno
- Ehime University Hospital
-
Toyama, Japonsko, 930-0194
- Dokončeno
- Toyama University Hospital
-
Ube, Japonsko, 755-8505
- Dokončeno
- Yamaguchi University Hospital
-
-
-
-
-
Seoul, Jižní Korea, 05030
- Dokončeno
- Konkuk University Medical Center
-
Seoul, Jižní Korea, 02447
- Dokončeno
- Kyunghee University Medical Center
-
Seoul, Jižní Korea, 135-710
- Dokončeno
- Samsung Medical Center
-
-
-
-
-
Ottawa, Kanada, K1N 6N5
- Nábor
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Floridablanca, Kolumbie, 681004
- Dokončeno
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Kolumbie, 50021
- Aktivní, ne nábor
- Instituto Neurológico de Colombia
-
-
-
-
-
Monterrey, Mexiko, 64710
- Dokončeno
- i Can Oncology Center
-
Tlalnepantla, Mexiko, 54055
- Nábor
- Clinical Research Institute S.C.
-
-
-
-
-
Berlin, Německo, 13347
- Aktivní, ne nábor
- Judisches Krankenhaus Berlin
-
Bochum, Německo, 44791
- Dokončeno
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Německo, 6120
- Aktivní, ne nábor
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Německo, 30625
- Aktivní, ne nábor
- Medizinische Hochschule Hannover
-
Leipzig, Německo, 4103
- Dokončeno
- Universitaetsklinikum Leipzig
-
Potsdam, Německo, 14471
- Dokončeno
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Chorzów, Polsko, 41 500
- Dokončeno
- Centrum Medyczne
-
Krakow, Polsko, 30 539
- Dokončeno
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Polsko, 20 093
- Dokončeno
- Prywatny Gabinet Lekarski
-
Poznan, Polsko, 61 731
- Aktivní, ne nábor
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Almada, Portugalsko, 2805-267
- Aktivní, ne nábor
- Hospital Garcia de Orta
-
Braga, Portugalsko, 4710-243
- Dokončeno
- Hospital de Braga
-
Porto, Portugalsko, 4200 319
- Aktivní, ne nábor
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Birmingham, Spojené království, B15 2TH
- Dokončeno
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, Spojené království, EX2 5DW
- Dokončeno
- Royal Devon & Exeter Hospital
-
Glasgow, Spojené království, G514TF
- Aktivní, ne nábor
- NHS Greater Glasgow and Clyde
-
London, Spojené království, NW3 2QG
- Dokončeno
- Royal Free Hospital
-
Sheffield, Spojené království, S10 2 JF
- Aktivní, ne nábor
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
Colorado
-
Centennial, Colorado, Spojené státy, 80112
- Aktivní, ne nábor
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, Spojené státy, 33067
- Dokončeno
- Healthcare Innovations Institute Inc
-
Maitland, Florida, Spojené státy, 32751
- Dokončeno
- Neurology Associates PA
-
Miami, Florida, Spojené státy, 33136
- Aktivní, ne nábor
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, Spojené státy, 30912
- Dokončeno
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- Dokončeno
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Dokončeno
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02111
- Dokončeno
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, Spojené státy, 48073
- Dokončeno
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64128
- Dokončeno
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, Spojené státy, 10032
- Dokončeno
- The Neurological Institute of New York
-
Patchogue, New York, Spojené státy, 11772
- Dokončeno
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28204
- Dokončeno
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44195
- Aktivní, ne nábor
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, Spojené státy, 78756
- Dokončeno
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Aktivní, ne nábor
- Advocate Health - Aurora St. Luke's Medical Center
-
-
-
-
-
Kaohsiung City, Tchaj-wan, 88301
- Dokončeno
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Tchaj-wan, 100
- Aktivní, ne nábor
- National Taiwan University Hospital
-
Taipei, Tchaj-wan, 111
- Aktivní, ne nábor
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Hradec Králové, Česko, 500 05
- Aktivní, ne nábor
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Česko, 708 52
- Dokončeno
- Fakultni Nemocnice Ostrava
-
Pardubice, Česko, 53203
- Dokončeno
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Beijing, Čína, 100191
- Dokončeno
- Peking University Third Hospital
-
Beijing, Čína, 100034
- Dokončeno
- Peking University First Hospital
-
Beijing, Čína, 100053
- Aktivní, ne nábor
- Xuanwu Hospital ,Capital Medical University
-
Beijing, Čína, 100070
- Aktivní, ne nábor
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, Čína, 130021
- Aktivní, ne nábor
- The First Hospital of Jilin University
-
Changsha, Čína, 410008
- Dokončeno
- Xiangya Hospital Central South University
-
Changsha, Čína, 410008
- Aktivní, ne nábor
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, Čína, 610072
- Dokončeno
- Sichuan Provincial Peoples Hospital
-
Chifeng, Čína, 024000
- Dokončeno
- Chifeng Municipal Hospital
-
Fuzhou, Čína, 350001
- Aktivní, ne nábor
- Fujian Medical University Union Hospital
-
Guangzhou, Čína, 510080
- Aktivní, ne nábor
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Čína, 250012
- Aktivní, ne nábor
- Qilu Hospital of Shandong University
-
Jinan, Čína, 250014
- Dokončeno
- Qianfoshan hospital of Shandong Province
-
Nanchang, Čína, 330006
- Aktivní, ne nábor
- The First Affiliated Hospital of NanChang University
-
Shanghai, Čína, 200336
- Dokončeno
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, Čína, 200040
- Aktivní, ne nábor
- Huashan Hospital Fudan University
-
Wuhan, Čína, 430023
- Dokončeno
- Renmin Hospital of Wuhan University
-
Xi'an, Čína, 710032
- Dokončeno
- Tangdu hospital the Fourth Military Medical
-
Xi'an, Čína, 710075
- Aktivní, ne nábor
- Xi 'an GaoXin Hospital
-
-
-
-
-
Athens, Řecko, 12462
- Nábor
- Attikon General Hospital of Athens
-
Athens, Řecko, 11527
- Dokončeno
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Řecko, 26504
- Dokončeno
- Patras University Hospital
-
Thessaloniki, Řecko, 54636
- Nábor
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Alicante, Španělsko, 03010
- Aktivní, ne nábor
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Španělsko, 8035
- Dokončeno
- Hosp Univ Vall D Hebron
-
Bilbao, Španělsko, 48013
- Aktivní, ne nábor
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Španělsko, 20014
- Dokončeno
- Hosp. Univ. Donostia
-
Madrid, Španělsko, 28040
- Dokončeno
- Hosp. Clinico San Carlos
-
Seville, Španělsko, 41009
- Aktivní, ne nábor
- Hosp. Virgen Macarena
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Ostatní jména:
|
|
Komparátor placeba: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Časové okno: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Časové okno: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Časové okno: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Časové okno: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Časové okno: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Časové okno: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Časové okno: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Časové okno: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Časové okno: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Časové okno: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Časové okno: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Časové okno: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Časové okno: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Časové okno: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Časové okno: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Časové okno: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Časové okno: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Časové okno: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci nervového systému
- Patologické procesy
- Neuromuskulární onemocnění
- Chronické onemocnění
- Atributy nemoci
- Autoimunitní onemocnění
- Onemocnění imunitního systému
- Onemocnění periferního nervového systému
- Autoimunitní onemocnění nervového systému
- Demyelinizační onemocnění
- Polyneuropatie
- Polyradikuloneuropatie
- Patologické stavy, příznaky a symptomy
- Polyradikuloneuropatie, chronická zánětlivá demyelinizace
Další identifikační čísla studie
- CR109195
- 80202135CDP3001 (Jiný identifikátor: Janssen Research & Development, LLC)
- 2021-003234-37 (Číslo EudraCT)
- 2023-508425-28-00 (Identifikátor registru: EUCT number)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .